IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors
This is a multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, antitumor activity of IPH5401 (anti C5aR) in combination with Durvalumab (MEDI4736) in Adult Subjects with selected advanced solid tumors.
Advanced Solid Tumors
BIOLOGICAL: IPH5401 and Durvalumab
Occurrence of Drug Limited Toxicities (DLTs), To assess the occurrence of Drug Limited Toxicities (DLTs), From Time of First dose assessed up to 6 weeks|Adverse events (AEs), To evaluate the safety profile, From screening visit up to 30 days after the last dose of study medication
Objective Response Rate, Rate of patients in complete or partial response according to RECIST 1.1, up to 12 months|Duration of Response, duration between the complete or partial response and the first documented progression, 2 years and 9 months|Progression Free Survival, time between the start of treatment and the first documented progression or death, 2 years and 9 months
This is a multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, antitumor activity of IPH5401 (anti C5aR) in combination with Durvalumab (MEDI4736) in Adult Subjects with selected advanced solid tumors.